In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 300 of 392

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	16 July 2025
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]	Highly specialised technology	TBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]	Highly specialised technology	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594	Technology appraisal guidance	TBC
Pegcetacoplan for treating geographic atrophy [ID4041]	Technology appraisal guidance	TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]	Technology appraisal guidance	TBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]	Highly specialised technology	TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]	Technology appraisal guidance	11 December 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]	Technology appraisal guidance	28 May 2025
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381	Technology appraisal guidance	16 April 2025
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]	Technology appraisal guidance	TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]	Technology appraisal guidance	TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
PillCam COLON 2 for investigation of the colon through direct visualisation	Diagnostics guidance	17 July 2025
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353	Technology appraisal guidance	TBC
Pneumonia: diagnosis and management (update)	NICE guideline	TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance	TBC
Pralsetinib for thyroid cancer [ID4018]	Technology appraisal guidance	TBC
Pulsed field ablation for atrial fibrillation	Interventional procedures guidance	14 August 2025
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Rehabilitation for chronic neurological disorders including acquired brain injury	NICE guideline	16 July 2025
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]	Technology appraisal guidance	TBC
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]	Technology appraisal guidance	TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007	Technology appraisal guidance	TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)	Technology appraisal guidance	TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]	Technology appraisal guidance	18 June 2025
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Robot-assisted surgery for orthopaedic procedures: early value assessment	Health technology evaluation	31 March 2025
Robot-assisted surgery for soft-tissue procedures: early value assessment	Health technology evaluation	31 March 2025
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]	Technology appraisal guidance	TBC

Results per page

10
25
50
All